https://ir.beonemedicines.com/ 2026-06-04 weekly https://ir.beonemedicines.com/stock-information 2026-06-04 weekly https://ir.beonemedicines.com/stock-information/analyst-coverage 2026-06-04 weekly https://ir.beonemedicines.com/stock-information/stock-chart 2026-06-04 weekly https://ir.beonemedicines.com/filings-financials/financial-document-library 2026-06-04 weekly https://ir.beonemedicines.com/filings-financials/sec-filings 2026-06-04 weekly https://ir.beonemedicines.com/filings-financials/shareholder-meeting-materials 2026-06-04 weekly https://ir.beonemedicines.com/media-resources/pressreleases 2026-06-04 weekly https://ir.beonemedicines.com/governance/documents-charters 2026-06-04 weekly https://ir.beonemedicines.com/governance/committee-composition 2026-06-04 weekly https://ir.beonemedicines.com/governance/rbs-report 2026-06-04 weekly https://ir.beonemedicines.com/ir-resources/email-alert 2026-06-04 weekly https://ir.beonemedicines.com/ir-resources/ir-contact 2026-06-04 weekly https://ir.beonemedicines.com/news/beone-medicines-beqalzitm-sonrotoclax-approved-by-us-fda-as-first-and-only-bcl2-inhibitor-for/a57256f1-5e36-427a-94c3-2b6be7f2bfb9 2026-06-04 https://ir.beonemedicines.com/news/beone-medicines-sets-the-pace-in-oncology-at-asco-and-eha-2026-with-60-abstracts/4a61ff99-a44a-4fcd-b82a-e94566abf124 2026-06-04